ReportAlert.info - CSL Limited (CSL:ASX) Publishes its Sixth Corporate Responsibility Report - Our Corporate Responsibility 2014
The report details the company's performance across six key corporate responsibility priority areas
December 4, 2014 /3BL Media/ - CSL Limited has published its sixth Corporate Responsibility Report - Our Corporate Responsibility 2014 - available at
www.csl.com.au/corporate-responsibility.htm
The report details CSL’s performance across six key corporate responsibility priority areas for the period 1 July 2013 and 30 June 2014.
Achievements and challenges include:
- Economic contribution direct to local economies of US$4.9 billion, a 5% increase on the previous year, including global community investment of US$32.8 million to patient, biomedical and local communities;
- Research and Development investment of US$466 million; with more than 40 clinical studies in operation across its pipeline. Achieved 22 product registrations/indications for serious diseases in various markets, an increase on the previous year;
- 179 GMP regulatory audits of its manufacturing facilities with no impact on CSL's product marketing licences. Across its extensive portfolio of products, CSL responded to two safety related product recalls in the reporting period;
- Second consecutive year of 7% growth in the total workforce, reaching 13,468 employees as at 30 June 2014. Health and safety performance saw lost time due to injury (LTIFR), lost days (DLFR) and incidences of medical treatment (MTIFR) reduce by 20%, 30% and 12% respectively;
- Across its global operations, CSL maintained compliance with all environmental laws and regulations. With an expanding facility footprint, CSL experienced moderate increases in absolute numbers across our environmental indicators. During the reporting period the company commenced an enterprise-wide climate change risk assessment, taking into consideration updated observations and forecasts from the United Nations Intergovernmental Panel on Climate Change (IPCC).
The CSL Group has a combined heritage of outstanding contribution to medicine and human health with 98 years’ experience in the development and manufacture of vaccines and plasma protein biotherapies. With major facilities in Australia, Germany, Switzerland and the USA, CSL has over 12,000 employees working in more than 25 countries.
Please provide feedback on CSL’s Report, with survey responses helping to support the World Federation of Hemophilia:
www.csl.com.au/corporate-responsibility.htm
